Economic implications of bivalirudin in the cardiac catheterization laboratory

Reviews in Cardiovascular Medicine

Volumn 7, Issue SUPPL. 3, 2006, Pages

  Bakhai, Ameet ^a   Cohen, David J ^b  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antithrombotics; Bivalirudin; Ischemia; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; COST CONTROL; DRUG COST; DRUG RECEPTOR BINDING; HEALTH CARE COST; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; LOW DRUG DOSE; MEDICARE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; DRUG COSTS; HEART CATHETERIZATION; HIRUDINS; HUMANS; LABORATORIES, HOSPITAL; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 33846291878     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Annual Update. Dallas, TX: American Heart Association; 2005.
2. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprorein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
3. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
4. Steinhubl SR, Berger PB, Mann JT 3rd, et al., for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
5. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention. J Am Coll Cardiol. 2004;44:1792-1800.
6. Cohen DJ, O'Shea JC, Pacchiana CM, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. Am J Cardiol. 2002;89:61-64.
7. Heiat A, Mattera JA, Henry GA, et al. Trends in cost of percutaneous transluminal coronary angioplasty. Am J Manag Care. 1998;4:1667-1674.
8. Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 2000;102:2923-2929.
9. PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Praire ReoPro versus Integrilin Cost Evaluation (PRICE) trial. Am Heart J. 2001;141:402-409.
10. Peterson ED, Cowper PA, DeLong ER, et al. Acute and long-term cost implications of coronary stenting. J Am Coll Cardiol. 1999;33:1610-1618.
11. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
12. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol. 2004;43:513-518.
13. Moscucci M. Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new anti-thrombotic agents. J Invasive Cardiol. 2002;14: 55B-64B.
14. Ellis SG, Miller DP, Brown KJ, et al. In-hospital costs of percutaneous coronary revascularization. Critical determinants and implications. Circulation. 1995;92:741-747.
15. Lauer MA, Karweit JA, Cascade EF, et al. Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol. 2002;89:924-929.
16. Kugelmass AD, Cohen DJ, Brown PP, et al. Hospital resources consumed in treating complications associated with percutaneous coronary interventions. Am J Cardiol. 2006;97:322-327.
17. Lincoff AM, Bittl JA, Harrington PA, et al., for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
18. Lee MS, Makkar RR. Bivalirudin in acute coronary syndromes and percutaneous coronary intervention. Rev Cardiovasc Med. 2006;7: S27-S34.
19. Taira DA, Seto TB, Siegrist R, et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J. 2003;145:452-458.
20. Mark DB, Talley JD, Topoi EJ, et al., for the EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation. 1996;94:629-635.
21. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764-775.
22. ACUITY Trial. Available at: http://www.medscape.com/viewarticle/529634. Accessed April 14, 2006.
23. Angiomax Monograph. Available at: www.themedicinescompany.com/pdf/ Product%20Monograph%20ANG-PMN-011-04.pdf. Accessed April 13, 2006.